Childress Capital Advisors LLC Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Childress Capital Advisors LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 69.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 13,694 shares of the biopharmaceutical company’s stock after selling 31,257 shares during the quarter. Childress Capital Advisors LLC’s holdings in Pfizer were worth $363,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC bought a new stake in shares of Pfizer in the 4th quarter worth approximately $26,000. Gladius Capital Management LP raised its stake in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 38,015 shares during the period. Quarry LP purchased a new position in shares of Pfizer during the 2nd quarter valued at $31,000. Teachers Insurance & Annuity Association of America purchased a new stake in Pfizer during the third quarter valued at about $35,000. Finally, Joseph Group Capital Management increased its stake in shares of Pfizer by 168.3% in the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 771 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on PFE shares. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Wolfe Research assumed coverage on shares of Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. Guggenheim reduced their price objective on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, Citigroup decreased their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Down 1.1 %

Shares of Pfizer stock opened at $26.23 on Tuesday. The company has a 50-day simple moving average of $26.27 and a two-hundred day simple moving average of $27.85. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market capitalization of $148.62 billion, a PE ratio of 35.44, a price-to-earnings-growth ratio of 0.66 and a beta of 0.64.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.56%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is currently 232.44%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.